The genomic profile of HER2-amplified breast cancers: The influence of ER status

C. Marchiò, R. Natrajan, K. K. Shiu, M. B K Lambros, S. M. Rodriguez-Pinilla, D. S P Tan, C. J. Lord, D. Hungermann, K. Fenwick, N. Tamber, A. Mackay, J. Palacios, A. Sapino, H. Buerger, A. Ashworth, J. S. Reis-Filho

Research output: Contribution to journalArticle

Abstract

Expression profiling studies have suggested that HER2-amplified breast cancers constitute a heterogeneous group that may be subdivided according to their ER status: HER2-amplified ER-positive breast carcinomas that fall into the luminal B cluster; and HER2-amplified ER-negative cancers which form a distinct molecular subgroup, known as the erbB2 or HER2 subgroup. ER-negative breast cancer differs significantly from ER-positive disease in the pattern, type, and complexity of genetic aberrations. Here we have compared the genomic profiles of ER-positive and ER-negative HER2-amplified cancers using tiling path microarray-based comparative genomic hybridization (aCGH). Validation of the differentially amplified regions was performed in an independent series of 70 HER2-amplified breast cancers. Although HER2-amplified cancers had remarkably complex patterns of molecular genetic aberrations, ER-positive and ER-negative HER2-amplified breast carcinomas shared most molecular genetic features as defined by aCGH. Genome-wide Fisher's exact test analysis revealed that less than 1.5% of the genome was significantly differentially gained or lost in ER-positive versus ER-negative HER2-amplified cancers. However, two regions of amplification were significantly associated with ER-positive carcinomas, one of which mapped to 17q21.2 and encompassed GJC1, IGFBP4, TNS4, and TOP2A. Chromogenic in situ hybridization analysis of an independent validation series confirmed the association between ER status and TOP2A amplification. In conclusion, although hormone receptor status does not determine the overall genetic profile of HER2-amplified breast cancers, specific genetic aberrations may be characteristic of subgroups of HER2 breast cancers.

Original languageEnglish
Pages (from-to)399-407
Number of pages9
JournalJournal of Pathology
Volume216
Issue number4
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Breast Neoplasms
Molecular Biology
Neoplasms
Genome
Comparative Genomic Hybridization
In Situ Hybridization
Hormones
Carcinoma

Keywords

  • c-erb-B2
  • Comparative genomic hybridization
  • Microarray
  • Oestrogen receptor
  • Tissue microarrays
  • TOP2A

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Marchiò, C., Natrajan, R., Shiu, K. K., Lambros, M. B. K., Rodriguez-Pinilla, S. M., Tan, D. S. P., ... Reis-Filho, J. S. (2008). The genomic profile of HER2-amplified breast cancers: The influence of ER status. Journal of Pathology, 216(4), 399-407. https://doi.org/10.1002/path.2423

The genomic profile of HER2-amplified breast cancers : The influence of ER status. / Marchiò, C.; Natrajan, R.; Shiu, K. K.; Lambros, M. B K; Rodriguez-Pinilla, S. M.; Tan, D. S P; Lord, C. J.; Hungermann, D.; Fenwick, K.; Tamber, N.; Mackay, A.; Palacios, J.; Sapino, A.; Buerger, H.; Ashworth, A.; Reis-Filho, J. S.

In: Journal of Pathology, Vol. 216, No. 4, 12.2008, p. 399-407.

Research output: Contribution to journalArticle

Marchiò, C, Natrajan, R, Shiu, KK, Lambros, MBK, Rodriguez-Pinilla, SM, Tan, DSP, Lord, CJ, Hungermann, D, Fenwick, K, Tamber, N, Mackay, A, Palacios, J, Sapino, A, Buerger, H, Ashworth, A & Reis-Filho, JS 2008, 'The genomic profile of HER2-amplified breast cancers: The influence of ER status', Journal of Pathology, vol. 216, no. 4, pp. 399-407. https://doi.org/10.1002/path.2423
Marchiò C, Natrajan R, Shiu KK, Lambros MBK, Rodriguez-Pinilla SM, Tan DSP et al. The genomic profile of HER2-amplified breast cancers: The influence of ER status. Journal of Pathology. 2008 Dec;216(4):399-407. https://doi.org/10.1002/path.2423
Marchiò, C. ; Natrajan, R. ; Shiu, K. K. ; Lambros, M. B K ; Rodriguez-Pinilla, S. M. ; Tan, D. S P ; Lord, C. J. ; Hungermann, D. ; Fenwick, K. ; Tamber, N. ; Mackay, A. ; Palacios, J. ; Sapino, A. ; Buerger, H. ; Ashworth, A. ; Reis-Filho, J. S. / The genomic profile of HER2-amplified breast cancers : The influence of ER status. In: Journal of Pathology. 2008 ; Vol. 216, No. 4. pp. 399-407.
@article{18e85d8397f24c32a19c57b0d624e8f7,
title = "The genomic profile of HER2-amplified breast cancers: The influence of ER status",
abstract = "Expression profiling studies have suggested that HER2-amplified breast cancers constitute a heterogeneous group that may be subdivided according to their ER status: HER2-amplified ER-positive breast carcinomas that fall into the luminal B cluster; and HER2-amplified ER-negative cancers which form a distinct molecular subgroup, known as the erbB2 or HER2 subgroup. ER-negative breast cancer differs significantly from ER-positive disease in the pattern, type, and complexity of genetic aberrations. Here we have compared the genomic profiles of ER-positive and ER-negative HER2-amplified cancers using tiling path microarray-based comparative genomic hybridization (aCGH). Validation of the differentially amplified regions was performed in an independent series of 70 HER2-amplified breast cancers. Although HER2-amplified cancers had remarkably complex patterns of molecular genetic aberrations, ER-positive and ER-negative HER2-amplified breast carcinomas shared most molecular genetic features as defined by aCGH. Genome-wide Fisher's exact test analysis revealed that less than 1.5{\%} of the genome was significantly differentially gained or lost in ER-positive versus ER-negative HER2-amplified cancers. However, two regions of amplification were significantly associated with ER-positive carcinomas, one of which mapped to 17q21.2 and encompassed GJC1, IGFBP4, TNS4, and TOP2A. Chromogenic in situ hybridization analysis of an independent validation series confirmed the association between ER status and TOP2A amplification. In conclusion, although hormone receptor status does not determine the overall genetic profile of HER2-amplified breast cancers, specific genetic aberrations may be characteristic of subgroups of HER2 breast cancers.",
keywords = "c-erb-B2, Comparative genomic hybridization, Microarray, Oestrogen receptor, Tissue microarrays, TOP2A",
author = "C. Marchi{\`o} and R. Natrajan and Shiu, {K. K.} and Lambros, {M. B K} and Rodriguez-Pinilla, {S. M.} and Tan, {D. S P} and Lord, {C. J.} and D. Hungermann and K. Fenwick and N. Tamber and A. Mackay and J. Palacios and A. Sapino and H. Buerger and A. Ashworth and Reis-Filho, {J. S.}",
year = "2008",
month = "12",
doi = "10.1002/path.2423",
language = "English",
volume = "216",
pages = "399--407",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - The genomic profile of HER2-amplified breast cancers

T2 - The influence of ER status

AU - Marchiò, C.

AU - Natrajan, R.

AU - Shiu, K. K.

AU - Lambros, M. B K

AU - Rodriguez-Pinilla, S. M.

AU - Tan, D. S P

AU - Lord, C. J.

AU - Hungermann, D.

AU - Fenwick, K.

AU - Tamber, N.

AU - Mackay, A.

AU - Palacios, J.

AU - Sapino, A.

AU - Buerger, H.

AU - Ashworth, A.

AU - Reis-Filho, J. S.

PY - 2008/12

Y1 - 2008/12

N2 - Expression profiling studies have suggested that HER2-amplified breast cancers constitute a heterogeneous group that may be subdivided according to their ER status: HER2-amplified ER-positive breast carcinomas that fall into the luminal B cluster; and HER2-amplified ER-negative cancers which form a distinct molecular subgroup, known as the erbB2 or HER2 subgroup. ER-negative breast cancer differs significantly from ER-positive disease in the pattern, type, and complexity of genetic aberrations. Here we have compared the genomic profiles of ER-positive and ER-negative HER2-amplified cancers using tiling path microarray-based comparative genomic hybridization (aCGH). Validation of the differentially amplified regions was performed in an independent series of 70 HER2-amplified breast cancers. Although HER2-amplified cancers had remarkably complex patterns of molecular genetic aberrations, ER-positive and ER-negative HER2-amplified breast carcinomas shared most molecular genetic features as defined by aCGH. Genome-wide Fisher's exact test analysis revealed that less than 1.5% of the genome was significantly differentially gained or lost in ER-positive versus ER-negative HER2-amplified cancers. However, two regions of amplification were significantly associated with ER-positive carcinomas, one of which mapped to 17q21.2 and encompassed GJC1, IGFBP4, TNS4, and TOP2A. Chromogenic in situ hybridization analysis of an independent validation series confirmed the association between ER status and TOP2A amplification. In conclusion, although hormone receptor status does not determine the overall genetic profile of HER2-amplified breast cancers, specific genetic aberrations may be characteristic of subgroups of HER2 breast cancers.

AB - Expression profiling studies have suggested that HER2-amplified breast cancers constitute a heterogeneous group that may be subdivided according to their ER status: HER2-amplified ER-positive breast carcinomas that fall into the luminal B cluster; and HER2-amplified ER-negative cancers which form a distinct molecular subgroup, known as the erbB2 or HER2 subgroup. ER-negative breast cancer differs significantly from ER-positive disease in the pattern, type, and complexity of genetic aberrations. Here we have compared the genomic profiles of ER-positive and ER-negative HER2-amplified cancers using tiling path microarray-based comparative genomic hybridization (aCGH). Validation of the differentially amplified regions was performed in an independent series of 70 HER2-amplified breast cancers. Although HER2-amplified cancers had remarkably complex patterns of molecular genetic aberrations, ER-positive and ER-negative HER2-amplified breast carcinomas shared most molecular genetic features as defined by aCGH. Genome-wide Fisher's exact test analysis revealed that less than 1.5% of the genome was significantly differentially gained or lost in ER-positive versus ER-negative HER2-amplified cancers. However, two regions of amplification were significantly associated with ER-positive carcinomas, one of which mapped to 17q21.2 and encompassed GJC1, IGFBP4, TNS4, and TOP2A. Chromogenic in situ hybridization analysis of an independent validation series confirmed the association between ER status and TOP2A amplification. In conclusion, although hormone receptor status does not determine the overall genetic profile of HER2-amplified breast cancers, specific genetic aberrations may be characteristic of subgroups of HER2 breast cancers.

KW - c-erb-B2

KW - Comparative genomic hybridization

KW - Microarray

KW - Oestrogen receptor

KW - Tissue microarrays

KW - TOP2A

UR - http://www.scopus.com/inward/record.url?scp=55249092391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249092391&partnerID=8YFLogxK

U2 - 10.1002/path.2423

DO - 10.1002/path.2423

M3 - Article

C2 - 18810758

AN - SCOPUS:55249092391

VL - 216

SP - 399

EP - 407

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -